Riley I D, Lehmann D, Alpers M P, Marshall T F, Gratten H, Smith D
Lancet. 1986 Oct 18;2(8512):877-81. doi: 10.1016/s0140-6736(86)90409-5.
In three double-blind placebo-controlled trials of pneumococcal capsular polysaccharide vaccines against death from acute lower-respiratory-tract infections (ALRI), children were vaccinated at 6 months to 5 years of age. The efficacy of the vaccines against ALRI as the sole cause of death was estimated at 59% in children vaccinated when younger than 5 years (p = 0.008) and 50% in children vaccinated when younger than 2 years (p = 0.043). Mortality from all causes was 19% less in the vaccinated group.
在三项针对肺炎球菌荚膜多糖疫苗预防急性下呼吸道感染（ALRI）所致死亡的双盲安慰剂对照试验中，对6个月至5岁的儿童进行了疫苗接种。对于5岁以下接种疫苗的儿童，该疫苗预防ALRI作为唯一死亡原因的有效性估计为59%（p = 0.008），对于2岁以下接种疫苗的儿童，有效性为50%（p = 0.043）。接种疫苗组的全因死亡率降低了19%。
